The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression

Psychoneuroendocrinology

Volumn 38, Issue 1, 2013, Pages 115-121

  Lembke, Anna ^a   Gomez, Rowena ^a   Tenakoon, Lakshika ^a   Keller, Jennifer ^a   Cohen, Gregory ^b   Williams, Gordon H ^c   Kraemer, Fredric B ^a   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cortisol; Fludrocortisone; Hippocampus; HPA axis; Mineralocorticoid receptor; Psychotic major depression

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MALE; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; PSYCHOTIC MAJOR DEPRESSION; TREATMENT RESPONSE;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; AREA UNDER CURVE; DEPRESSIVE DISORDER, MAJOR; FEEDBACK, PHYSIOLOGICAL; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RECEPTORS, MINERALOCORTICOID;

EID: 84870393620     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.05.006     Document Type: Article

References (31)

1. Agarwal J.K., Coupry F., et al. Physiological activity and receptor binding of 9-fludrocortisone. Biochem. Biophys. Res. Commun. 1977, 78:747-753.
2. Barden N., Reul J.M., et al. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary adrenocortical system?. Trends Neurosci. 1995, 18:6-11.
3. Belanoff J.K., Rothschild A.J., et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry 2002, 52(5):386-392.
4. Binneman B., Feltner D., et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 2008, 165(5):617-620.
5. Brady L.S., Whitfield H.J., et al. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralcorticoid receptor gene expression in rat brain. J. Clin. Invest. 1991, 87:831-837.
6. Buckley T.M., Mullen B.C., et al. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology 2007, 32(8-10):859-864.
7. Carroll B.J. The dexamethasone suppression test for melancholia. Br. J. Psychiatry 1982, 140:292-304.
8. de Kloet E.R., Joels M., et al. Stress and the brain: from adaptation to disease. Nat. Rev. 2005, 6.
9. Debattista C., Belanoff J., et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 2006.
10. DeRijk R.H., de Kloet E.R. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur. J. Pharmacol. 2008, 583(2-3):303-311.
11. First M.B., Spitzer R.L. Structured Clinical Interview Diagnostic (SCID) for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) 1997, American Psychiatric Press.
12. Gomez R.G., Fleming S.H., et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol. Psychiatry 2006, 60(5):472-478.
13. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
14. Heim C., Newport D.J., et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. J. Am. Med. Assoc. 2000, 284(5):592-597.
15. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33:181-214.
16. Holsboer F., Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 2008, 583(2-3):350-357.
17. Jahn H., Schick M., et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch. Gen. Psychiatry 2004, 61(12):1235-1244.
18. López J.F., Chalmers D.T., et al. Regulation of Serotonin1A glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 1998, 43(8):547-573.
19. Nelson J.C.M.D., Davis J.M.M.D. DST studies in psychotic depression: a meta-analysis. Am. J. Psychiatry 1997, 154(11):1497-1503.
20. Otte C., Hinkelmann K., et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J. Psychiatr. Res. 2010, 44(6):339-346.
21. Otte C., Jahn H., et al. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci. 2003, 73(14):1835-1845.
22. Overall J.D.G. Brief psychiatric rating scale. Psychol. Rep. 1962, 10:799.
23. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31(9):464-468.
24. Posener J.A., DeBattista C., et al. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch. Gen. Psychiatry 2000, 57(8):755-760.
25. Reul J.M., Stec I., et al. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133:312-320.
26. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralcorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992, 55:621-626.
27. Thase M.E., Hersen M., et al. Validation of a Hamilton subscale for endogenomorphic depression. J. Affect. Disord. 1983, 5(3):267-278.
28. Wolkowitz O.MM.D., Reus V.I.M.D., et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psychiatry 1999, 45:1070-1074.
29. Yau J.L., Hibberd C., et al. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res. Mol. Brain Res. 2002, 106:117-123.
30. Young E.A., Lopez J.F., et al. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry 2003, 60(1):24-28.
31. Zobel A.W., Nickel T., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34(3):171-181.